Task Force Information
Objectives
Consumers, the scientific community, regulators and the food and dietary supplement industry show increasing interest in probiotics and their health benefits. The attention of the task force is thus focused on the understanding of the role of probiotics in health and disease, their mechanisms of action while increasing awareness of their direct/indirect benefits on health.
Task Force Members
Dr Arthur Ouwehand – Chair | International Flavors & Fragrances (IFF) | R&D Group Manager | FI |
Dr Luc Sterkman – Vice-Chair | Caelus Health | CEO | NL |
Prof. Marc Heyndrickx* – Co-Chair | Institute for Agricultural and Fisheries Research (ILVO) | Scientific Director | BE |
Dr Gabriele Gross | Mead Johnson Nutrition / Reckitt | Head of Emerging Sciences | NL |
Dr Benjamin Anderschou Holbech Jensen* | University of Copenhagen | Assist. Professor, Head of Nutritional Immunology | DK |
Dr Jonathan Lane | H&H Group | Senior Manager, Global Research | IE |
Dr Renaud Mestdagh | Cargill | Senior Scientist Infant Nutrition | BE |
Dr Delphine Saulnier | Novozymes | Science Manager | DE |
Dr Nikoletta Vidra | Yakult Europe | BE | |
Dr Adrienne Weiss | Yili Innovation Center Europe | Innovation Project Leader | NL |
Ms Naomi Venlet | ILSI Europe | Scientific Project Manager | BE |
* Scientific Advisors
Contact Information
For more detailed information, please contact Naomi Venlet at nvenlet@ilsieurope.be
Activity Overview
Mapping of probiotics and their activities in the small intestine - Ongoing -
Objectives
This activity will lead to a better understanding of the mode of action of probiotics in the small intestine, and to identify the most important gaps that still need to be filled. Ultimately, the knowledge gained from this project should help improve clinical research on probiotic efficacy.
Probiotics and pregnancy - Upcoming -
Objectives
This activity aims to review and publish evidence on possible influences of the type of carbohydrates co-ingested with proteins, on post-prandial and longer-term protein utilization. Results may be applied in selecting carbohydrates to help compensate for poorer quality or intakes/utilisation of proteins (e.g. plant-based diets, ageing populations), and also highlighting research gaps.
Expected results
Peer reviewed publication
Postbiotics - Upcoming -
Objectives
Seek consumer, Health care practitioners and regulatory authorities input to frame a subsequent review paper on postbiotics, but with a focus on consumer concerns, knowledge gaps and misconceptions.
Expected results
Peer reviewed publication
Expert Groups
Benefits, challenges, and opportunities with changes in the maternal microbiome before and during pregnancy
Background and objectives
During pregnancy, especially during the third trimester, the maternal microbiota is undergoing considerable changes in the gut, the vagina and, as recently shown, the endometrium. Interestingly, the maternal microbiome has now emerged as an important factor for a healthy pregnancy as well as a cause of pregnancy-related health issues e.g. preterm birth. Indeed, emerging research has started to link microbial dysbiosis and specific microbial populations with pregnancy complications. Thus, it is important to understand the context of physiological temporal microbial changes during pregnancy and mechanisms by which these changes can impact health outcomes. Furthermore, the use of probiotics during pregnancy is not a standard practice, however, given the importance of the microbiota for various health outcomes, it is crucial to better understand maternal microbiota changes, natural or induced, before and during pregnancy, their impact on maternal health and underlying mechanisms of action, as well the potential role of probiotics to optimize maternal health outcomes based on these insights.
Output
This activity will highlight mother and/or infant health outcomes associated with changes in the maternal microbiota before and during pregnancy. It will detail the mechanistic consequences of maternal microbiota changes, and discuss early observations from probiotic clinical studies, to identify opportunities for optimized use of probiotics during pregnancy in a narrative review.
Expert group members
Dr Gabriele Gross | Reckitt Benckiser/Mead Johnson Nutrition | Principal Scientist / Project Leader | NL |
Dr Jonathan Lane | H&H group | Associate Director | IE |
Dr Nikoletta Vidra | Yakult Europe | BE | |
Dr Adrienne Weiss | Yili Innovation Center Europe | Innovation Project Leader | NL |
Dr Maria Carmen Collado | Spanish National Research Council | ES | |
Mr Eduard Flores Ventura | Spanish National Research Council | Researcher | ES |
Prof Sarah Lebeer | University of Antwerp | Research Professor | BE |
Prof Yvan Vandenplas | University of Brussels | Professor | BE |
Associate Prof Flavia Indrio | University of Bari | Associate Professor of Paediatrics | IT |
Ms Naomi Venlet | ILSI Europe | Scientific Project Manager | BE |
Mapping of probiotics and their activities in the small intestine
Background and Objectives
The knowledge of probiotics activity in humans is predominantly based on a reflection of what can be gathered in stool samples. However, many diseases have their origin in or are associated with the small intestine, such as certain diarrhoeas, auto-immune and celiac disease and metabolic syndrome. The aim of this activity is to look at the different barriers functions, microbial composition and physiology of the small intestine (duodenum, jejunum, ileum), models and technologies currently available to assess survival and understand how probiotics interact and act on this part of the gastro-intestinal (GI) tract.
Output
This activity will lead to a better understanding of the mode of action of probiotics in the small intestine, and to identify the most important gaps that still need to be filled. Ultimately, the knowledge gained from this project should help improve clinical research on probiotic efficacy.
Expert Group Members
Dr Benjamin Anderschou Holbech Jensen – Chair | University of Copenhagen | Leader Assoc. Prof. Nutritional Immunology | DK |
Dr Arthur Ouwehand – Vice-Chair | International Flavors & Fragrances (IFF) | R&D Group Manager | FI |
Prof. Marc Heyndrickx | Institute for Agriculture and Fisheries Research (ILVO) | Scientific Director | BE |
Drs Daisy Jonkers | Maastricht University | Associate Professor | NL |
Prof. Alan Mackie | University of Leeds | Head of the School of Food Science & Nutrition | UK |
Dr Sam Millet | Institute for Agriculture and Fisheries Research (ILVO) | Research Scientist | BE |
Dr Malwina Naghibi | ADM | Senior Medical Scientific Liaison | UK |
Dr Simone Isling Pærregaard | University of Copenhagen | Postdoc | DK |
Dr Bruno Pot | Yakult Europe | Science Director | NL |
Dr Delphine Saulnier | Novozymes | Science Manager | DE |
Prof. Dr Christian Sina | Institute of Nutritional Medicine University of Lübeck | Director | DE |
Dr Luc Sterkman | Caelus Health | Chief Executive Officer | NL |
Dr Pieter van den Abbeele | Cryptobiotix | CSO & Co-founder at Cryptobiotix | BE |
Dr Erwin Zoetendal | Wageningen University | Associate Professor | NL |
Ms Naomi Venlet | ILSI Europe | Scientific Project Manager | BE |
Publications
Books
No results.
Multimedia
Introductory video
Posters
Exploring the Interactions between Probiotics and Health
Webinars
'Toolsets for Mining the gut Microbiome to Enable Precision Nutrition'
Watch the Webinar
'Understanding Prebiotic and Probiotic Mechanisms that Drive Health Benefits'
Watch the Webinar
Completed Expert Groups
Overview of completed activities since 2021
-
Prediction of individual responses to prebiotics and probiotics intervention (collaboration Prebiotics Task Force)
-
Joint nutrition cluster activity on ‘mechanistic insights into the gut-brain axis' in collaboration with Early Nutrition and Long-Term Health; Health Benefit Assessment of Foods; Nutrition, Immunity & Inflammation; Nutrition & Brain Health and Prebiotics Task Forces
-
Updated concise monograph - Dietary Probiotics, Prebiotics and the Gut Microbiota in Human Health (collaboration with Probiotics Task Force)